{"url_path":"/sec/pbh/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1295947/0001295947-26-000016-index.html","accession_number":"0001295947-26-000016","cik":"0001295947","ticker":"PBH","issuer_name":"Prestige Consumer Healthcare Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1295947/0001295947-26-000016-index.html","primary_entity_key":"0001295947","primary_entity_name":"Prestige Consumer Healthcare Inc."},"word_count":723,"has_tables":true,"body_markdown":"pbh-20260331\n00012959472026FYFALSEConsolidated Statements of Income (Loss) and Comprehensive Income (Loss)Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)reportable segmentsiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:purepbh:segmentpbh:supplierpbh:votepbh:distribution_centerpbh:manufacturing_facilitypbh:manufacturer00012959472025-04-012026-03-3100012959472025-09-3000012959472026-05-120001295947us-gaap:ProductMember2025-04-012026-03-310001295947us-gaap:ProductMember2024-04-012025-03-310001295947us-gaap:ProductMember2023-04-012024-03-310001295947us-gaap:ProductAndServiceOtherMember2025-04-012026-03-310001295947us-gaap:ProductAndServiceOtherMember2024-04-012025-03-310001295947us-gaap:ProductAndServiceOtherMember2023-04-012024-03-3100012959472024-04-012025-03-3100012959472023-04-012024-03-3100012959472026-03-3100012959472025-03-310001295947us-gaap:CommonStockMember2023-03-310001295947us-gaap:AdditionalPaidInCapitalMember2023-03-310001295947us-gaap:TreasuryStockCommonMember2023-03-310001295947us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001295947us-gaap:RetainedEarningsMember2023-03-3100012959472023-03-310001295947us-gaap:AdditionalPaidInCapitalMember2023-04-012024-03-310001295947us-gaap:CommonStockMember2023-04-012024-03-310001295947us-gaap:TreasuryStockCommonMember2023-04-012024-03-310001295947us-gaap:RetainedEarningsMember2023-04-012024-03-310001295947us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012024-03-310001295947us-gaap:CommonStockMember2024-03-310001295947us-gaap:AdditionalPaidInCapitalMember2024-03-310001295947us-gaap:TreasuryStockCommonMember2024-03-310001295947us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001295947us-gaap:RetainedEarningsMember2024-03-3100012959472024-03-310001295947us-gaap:AdditionalPaidInCapitalMember2024-04-012025-03-310001295947us-gaap:CommonStockMember2024-04-012025-03-310001295947us-gaap:TreasuryStockCommonMember2024-04-012025-03-310001295947us-gaap:RetainedEarningsMember2024-04-012025-03-310001295947us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012025-03-310001295947us-gaap:CommonStockMember2025-03-310001295947us-gaap:AdditionalPaidInCapitalMember2025-03-310001295947us-gaap:TreasuryStockCommonMember2025-03-310001295947us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001295947us-gaap:RetainedEarningsMember2025-03-310001295947us-gaap:AdditionalPaidInCapitalMember2025-04-012026-03-310001295947us-gaap:CommonStockMember2025-04-012026-03-310001295947us-gaap:TreasuryStockCommonMember2025-04-012026-03-310001295947us-gaap:RetainedEarningsMember2025-04-012026-03-310001295947us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012026-03-310001295947us-gaap:CommonStockMember2026-03-310001295947us-gaap:AdditionalPaidInCapitalMember2026-03-310001295947us-gaap:TreasuryStockCommonMember2026-03-310001295947us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001295947us-gaap:RetainedEarningsMember2026-03-310001295947pbh:SydneyAustraliaMember2026-03-310001295947country:SG2026-03-310001295947srt:MinimumMemberus-gaap:BuildingMember2026-03-310001295947srt:MaximumMemberus-gaap:BuildingMember2026-03-310001295947srt:MinimumMemberus-gaap:OtherMachineryAndEquipmentMember2026-03-310001295947srt:MaximumMemberus-gaap:OtherMachineryAndEquipmentMember2026-03-310001295947srt:MinimumMemberus-gaap:ComputerEquipmentMember2026-03-310001295947srt:MaximumMemberus-gaap:ComputerEquipmentMember2026-03-310001295947srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2026-03-310001295947srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2026-03-310001295947srt:MinimumMember2026-03-310001295947srt:MaximumMember2026-03-310001295947us-gaap:ShippingAndHandlingMember2025-04-012026-03-310001295947us-gaap:ShippingAndHandlingMember2024-04-012025-03-310001295947us-gaap:ShippingAndHandlingMember2023-04-012024-03-310001295947pbh:Pillar5Member2025-12-180001295947us-gaap:TradeAccountsReceivableMember2026-03-310001295947us-gaap:TradeAccountsReceivableMember2025-03-310001295947us-gaap:LoansReceivableMember2026-03-310001295947us-gaap:LoansReceivableMember2025-03-310001295947pbh:OtherAccountsReceivableMember2026-03-310001295947pbh:OtherAccountsReceivableMember2025-03-310001295947us-gaap:LandMember2026-03-310001295947us-gaap:LandMember2025-03-310001295947us-gaap:BuildingMember2026-03-310001295947us-gaap:BuildingMember2025-03-310001295947us-gaap:OtherMachineryAndEquipmentMember2026-03-310001295947us-gaap:OtherMachineryAndEquipmentMember2025-03-310001295947us-gaap:ComputerEquipmentMember2026-03-310001295947us-gaap:ComputerEquipmentMember2025-03-310001295947us-gaap:FurnitureAndFixturesMember2026-03-310001295947us-gaap:FurnitureAndFixturesMember2025-03-310001295947us-gaap:LeaseholdImprovementsMember2026-03-310001295947us-gaap:LeaseholdImprovementsMember2025-03-310001295947us-gaap:ConstructionInProgressMember2026-03-310001295947us-gaap:ConstructionInProgressMember2025-03-310001295947pbh:NorthAmericanOTCHealthcareMember2024-03-310001295947pbh:InternationalOTCHealthcareMember2024-03-310001295947pbh:NorthAmericanOTCHealthcareMember2024-04-012025-03-310001295947pbh:InternationalOTCHealthcareMember2024-04-012025-03-310001295947pbh:NorthAmericanOTCHealthcareMember2025-03-310001295947pbh:InternationalOTCHealthcareMember2025-03-310001295947pbh:NorthAmericanOTCHealthcareMember2025-04-012026-03-310001295947pbh:InternationalOTCHealthcareMember2025-04-012026-03-310001295947pbh:NorthAmericanOTCHealthcareMember2026-03-310001295947pbh:InternationalOTCHealthcareMember2026-03-3100012959472024-01-0800012959472025-12-182025-12-180001295947us-gaap:MeasurementInputLongTermRevenueGrowthRateMember2026-02-282026-02-280001295947us-gaap:MeasurementInputDiscountRateMember2026-02-282026-02-280001295947us-gaap:MeasurementInputCapRateMember2026-02-282026-02-280001295947pbh:IndefinitelivedTradenamesMember2025-03-310001295947pbh:FiniteLivedTradenamesandCustomerRelationshipsMember2025-03-310001295947pbh:IndefinitelivedTradenamesMember2025-04-012026-03-310001295947pbh:FiniteLivedTradenamesandCustomerRelationshipsMember2025-04-012026-03-310001295947pbh:IndefinitelivedTradenamesMember2026-03-310001295947pbh:FiniteLivedTradenamesandCustomerRelationshipsMember2026-03-310001295947pbh:IndefinitelivedTradenamesMemberpbh:NorthAmericanOTCHealthcareMember2026-03-310001295947pbh:FiniteLivedTradenamesandCustomerRelationshipsMemberpbh:NorthAmericanOTCHealthcareMember2026-03-310001295947pbh:IndefinitelivedTradenamesMemberpbh:InternationalOTCHealthcareMember2026-03-310001295947pbh:FiniteLivedTradenamesandCustomerRelationshipsMemberpbh:InternationalOTCHealthcareMember2026-03-310001295947pbh:FeminaxMember2025-10-312025-10-310001295947pbh:IndefinitelivedTradenamesMember2024-03-310001295947pbh:FiniteLivedTradenamesandCustomerRelationshipsMember2024-03-310001295947pbh:IndefinitelivedTradenamesMember2024-04-012025-03-310001295947pbh:FiniteLivedTradenamesandCustomerRelationshipsMember2024-04-012025-03-3100012959472025-02-282025-02-280001295947pbh:AssociatedMembersMember2025-02-282025-02-280001295947us-gaap:IntersegmentEliminationMemberpbh:AssociatedMembersMember2025-02-282025-02-2800012959472026-02-280001295947pbh:GEODISLogisticsLLCMember2024-10-010001295947pbh:A2021SeniorNotesMemberus-gaap:SeniorNotesMember2026-03-310001295947pbh:A2021SeniorNotesMemberus-gaap:SeniorNotesMember2025-03-310001295947pbh:SeniorNotes2019Memberus-gaap:SeniorNotesMember2026-03-310001295947pbh:SeniorNotes2019Memberus-gaap:SeniorNotesMember2025-03-310001295947us-gaap:RevolvingCreditFacilityMemberpbh:A2012ABLRevolverMember2026-03-310001295947pbh:A2012TermLoanMemberus-gaap:LoansPayableMember2012-01-310001295947pbh:A2012TermLoanMemberus-gaap:LoansPayableMember2012-01-312012-01-310001295947us-gaap:RevolvingCreditFacilityMemberpbh:A2012ABLRevolverMember2012-01-310001295947us-gaap:RevolvingCreditFacilityMemberpbh:A2012ABLRevolverMember2012-01-312012-01-310001295947us-gaap:RevolvingCreditFacilityMemberpbh:A2012ABLRevolverMember2023-12-070001295947us-gaap:RevolvingCreditFacilityMemberpbh:A2012ABLRevolverMember2023-12-080001295947pbh:A2019SeniorNotesMember2019-12-020001295947pbh:A2019SeniorNotesMemberus-gaap:SeniorNotesMember2019-12-022019-12-020001295947pbh:A2021SeniorNotesMember2021-03-010001295947pbh:A2021SeniorNotesMemberus-gaap:SeniorNotesMember2021-03-012021-03-010001295947pbh:A2012TermLoanMemberus-gaap:LoansPayableMember2024-04-012025-03-310001295947pbh:A2012TermLoanMemberus-gaap:LoansPayableMember2025-04-012026-03-310001295947us-gaap:IndirectGuaranteeOfIndebtednessMemberpbh:SeniorNotes2019Memberus-gaap:SeniorNotesMember2019-12-022019-12-020001295947us-gaap:IndirectGuaranteeOfIndebtednessMemberpbh:A2021SeniorNotesMemberus-gaap:SeniorNotesMember2021-03-012021-03-010001295947us-gaap:CarryingReportedAmountFairValueDisclosureMemberpbh:SeniorNotes2019Memberus-gaap:SeniorNotesMember2026-03-310001295947us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberpbh:SeniorNotes2019Memberus-gaap:SeniorNotesMember2026-03-310001295947us-gaap:CarryingReportedAmountFairValueDisclosureMemberpbh:SeniorNotes2019Memberus-gaap:SeniorNotesMember2025-03-310001295947us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberpbh:SeniorNotes2019Memberus-gaap:SeniorNotesMember2025-03-310001295947us-gaap:CarryingReportedAmountFairValueDisclosureMemberpbh:A2021SeniorNotesMemberus-gaap:SeniorNotesMember2026-03-310001295947us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberpbh:A2021SeniorNotesMemberus-gaap:SeniorNotesMember2026-03-310001295947us-gaap:CarryingReportedAmountFairValueDisclosureMemberpbh:A2021SeniorNotesMemberus-gaap:SeniorNotesMember2025-03-310001295947us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberpbh:A2021SeniorNotesMemberus-gaap:SeniorNotesMember2025-03-310001295947us-gaap:RestrictedStockMember2025-04-012026-03-310001295947us-gaap:RestrictedStockMember2024-04-012025-03-310001295947pbh:ShareRepurchaseProgramMember2025-04-012026-03-310001295947pbh:ShareRepurchaseProgramMember2024-04-012025-03-310001295947pbh:LongtermEquityIncentivePlan2005Member2014-05-310001295947pbh:LongtermEquityIncentivePlan2005Member2014-06-012014-06-3000012959472014-05-312014-05-3100012959472014-06-012014-06-300001295947pbh:LongTermIncentivePlan2020Member2020-06-230001295947us-gaap:EmployeeStockOptionMember2025-04-012026-03-310001295947pbh:RestrictedStockUnitsRSUsPerformanceStockUnitsPSUsMember2026-03-310001295947pbh:RestrictedStockUnitsRSUsPerformanceStockUnitsPSUsMember2025-04-012026-03-310001295947us-gaap:RestrictedStockUnitsRSUMember2025-04-012026-03-310001295947srt:DirectorMemberus-gaap:RestrictedStockUnitsRSUMember2025-04-012026-03-310001295947us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-04-012025-03-310001295947us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2025-04-012026-03-310001295947us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2023-04-012024-03-310001295947us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2022-04-012023-03-310001295947us-gaap:RestrictedStockUnitsRSUMember2023-03-310001295947us-gaap:RestrictedStockUnitsRSUMember2023-04-012024-03-310001295947us-gaap:RestrictedStockUnitsRSUMember2024-03-310001295947us-gaap:RestrictedStockUnitsRSUMember2024-04-012025-03-310001295947us-gaap:RestrictedStockUnitsRSUMember2025-03-310001295947us-gaap:RestrictedStockUnitsRSUMember2026-03-310001295947srt:MinimumMemberus-gaap:EmployeeStockOptionMember2025-04-012026-03-310001295947srt:MaximumMemberus-gaap:EmployeeStockOptionMember2025-04-012026-03-310001295947srt:MinimumMemberus-gaap:EmployeeStockOptionMember2024-04-012025-03-310001295947srt:MaximumMemberus-gaap:EmployeeStockOptionMember2024-04-012025-03-310001295947srt:MinimumMemberus-gaap:EmployeeStockOptionMember2023-04-012024-03-310001295947srt:MaximumMemberus-gaap:EmployeeStockOptionMember2023-04-012024-03-310001295947us-gaap:EmployeeStockOptionMember2024-04-012025-03-310001295947us-gaap:EmployeeStockOptionMember2023-04-012024-03-310001295947us-gaap:AccumulatedTranslationAdjustmentMember2026-03-310001295947us-gaap:AccumulatedTranslationAdjustmentMember2025-03-310001295947us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2026-03-310001295947us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-03-310001295947country:AU2025-04-012026-03-310001295947us-gaap:ForeignTaxJurisdictionOtherMember2025-04-012026-03-310001295947pbh:ContributionTrancheOneMember2025-04-012026-03-310001295947pbh:ContributionTrancheTwoMember2025-04-012026-03-310001295947pbh:ThirdPartyManufacturingMember2026-03-310001295947pbh:Top5BrandsMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesMember2025-04-012026-03-310001295947pbh:Top5BrandsMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesMember2024-04-012025-03-310001295947pbh:Top5BrandsMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesMember2023-04-012024-03-310001295947pbh:WalmartMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesMember2025-04-012026-03-310001295947pbh:WalmartMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesMember2024-04-012025-03-310001295947pbh:WalmartMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesMember2023-04-012024-03-310001295947pbh:AmazonMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesMember2025-04-012026-03-310001295947pbh:AmazonMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesMember2024-04-012025-03-310001295947pbh:AmazonMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesMember2023-04-012024-03-310001295947pbh:WalmartMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-04-012026-03-310001295947pbh:ManufacturersUnitedStatesCanadaAndAustraliaMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesMember2025-04-012026-03-310001295947us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesMember2025-04-012026-03-310001295947pbh:ManufacturersMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesMember2025-04-012026-03-310001295947us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesMember2024-04-012025-03-310001295947pbh:ManufacturersMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesMember2024-04-012025-03-310001295947pbh:ContractPharmacalCorporationMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesMember2024-04-012025-03-310001295947pbh:ContractPharmacalCorporationMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesMember2025-04-012026-03-310001295947pbh:ContractPharmacalCorporationMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesMember2023-04-012024-03-310001295947us-gaap:OperatingSegmentsMemberpbh:NorthAmericanOTCHealthcareMember2025-04-012026-03-310001295947us-gaap:OperatingSegmentsMemberpbh:InternationalOTCHealthcareMember2025-04-012026-03-310001295947us-gaap:IntersegmentEliminationMemberpbh:NorthAmericanOTCHealthcareMember2025-04-012026-03-310001295947us-gaap:OperatingSegmentsMemberpbh:NorthAmericanOTCHealthcareMember2024-04-012025-03-310001295947us-gaap:OperatingSegmentsMemberpbh:InternationalOTCHealthcareMember2024-04-012025-03-310001295947us-gaap:IntersegmentEliminationMemberpbh:NorthAmericanOTCHealthcareMember2024-04-012025-03-310001295947us-gaap:OperatingSegmentsMemberpbh:NorthAmericanOTCHealthcareMember2023-04-012024-03-310001295947us-gaap:OperatingSegmentsMemberpbh:InternationalOTCHealthcareMember2023-04-012024-03-310001295947us-gaap:IntersegmentEliminationMemberpbh:NorthAmericanOTCHealthcareMember2023-04-012024-03-310001295947pbh:AnalgesicsMemberpbh:NorthAmericanOTCHealthcareMember2025-04-012026-03-310001295947pbh:AnalgesicsMemberpbh:InternationalOTCHealthcareMember2025-04-012026-03-310001295947pbh:AnalgesicsMember2025-04-012026-03-310001295947pbh:CoughAndColdMemberpbh:NorthAmericanOTCHealthcareMember2025-04-012026-03-310001295947pbh:CoughAndColdMemberpbh:InternationalOTCHealthcareMember2025-04-012026-03-310001295947pbh:CoughAndColdMember2025-04-012026-03-310001295947pbh:WomensHealthMemberpbh:NorthAmericanOTCHealthcareMember2025-04-012026-03-310001295947pbh:WomensHealthMemberpbh:InternationalOTCHealthcareMember2025-04-012026-03-310001295947pbh:WomensHealthMember2025-04-012026-03-310001295947pbh:GastrointestinalMemberpbh:NorthAmericanOTCHealthcareMember2025-04-012026-03-310001295947pbh:GastrointestinalMemberpbh:InternationalOTCHealthcareMember2025-04-012026-03-310001295947pbh:GastrointestinalMember2025-04-012026-03-310001295947pbh:EyeAndEarCareMemberpbh:NorthAmericanOTCHealthcareMember2025-04-012026-03-310001295947pbh:EyeAndEarCareMemberpbh:InternationalOTCHealthcareMember2025-04-012026-03-310001295947pbh:EyeAndEarCareMember2025-04-012026-03-310001295947pbh:DermatologicalsMemberpbh:NorthAmericanOTCHealthcareMember2025-04-012026-03-310001295947pbh:DermatologicalsMemberpbh:InternationalOTCHealthcareMember2025-04-012026-03-310001295947pbh:DermatologicalsMember2025-04-012026-03-310001295947pbh:OralCareMemberpbh:NorthAmericanOTCHealthcareMember2025-04-012026-03-310001295947pbh:OralCareMemberpbh:InternationalOTCHealthcareMember2025-04-012026-03-310001295947pbh:OralCareMember2025-04-012026-03-310001295947pbh:OtherOtcMemberpbh:NorthAmericanOTCHealthcareMember2025-04-012026-03-310001295947pbh:OtherOtcMemberpbh:InternationalOTCHealthcareMember2025-04-012026-03-310001295947pbh:OtherOtcMember2025-04-012026-03-310001295947pbh:AnalgesicsMemberpbh:NorthAmericanOTCHealthcareMember2024-04-012025-03-310001295947pbh:AnalgesicsMemberpbh:InternationalOTCHealthcareMember2024-04-012025-03-310001295947pbh:AnalgesicsMember2024-04-012025-03-310001295947pbh:CoughAndColdMemberpbh:NorthAmericanOTCHealthcareMember2024-04-012025-03-310001295947pbh:CoughAndColdMemberpbh:InternationalOTCHealthcareMember2024-04-012025-03-310001295947pbh:CoughAndColdMember2024-04-012025-03-310001295947pbh:WomensHealthMemberpbh:NorthAmericanOTCHealthcareMember2024-04-012025-03-310001295947pbh:WomensHealthMemberpbh:InternationalOTCHealthcareMember2024-04-012025-03-310001295947pbh:WomensHealthMember2024-04-012025-03-310001295947pbh:GastrointestinalMemberpbh:NorthAmericanOTCHealthcareMember2024-04-012025-03-310001295947pbh:GastrointestinalMemberpbh:InternationalOTCHealthcareMember2024-04-012025-03-310001295947pbh:GastrointestinalMember2024-04-012025-03-310001295947pbh:EyeAndEarCareMemberpbh:NorthAmericanOTCHealthcareMember2024-04-012025-03-310001295947pbh:EyeAndEarCareMemberpbh:InternationalOTCHealthcareMember2024-04-012025-03-310001295947pbh:EyeAndEarCareMember2024-04-012025-03-310001295947pbh:DermatologicalsMemberpbh:NorthAmericanOTCHealthcareMember2024-04-012025-03-310001295947pbh:DermatologicalsMemberpbh:InternationalOTCHealthcareMember2024-04-012025-03-310001295947pbh:DermatologicalsMember2024-04-012025-03-310001295947pbh:OralCareMemberpbh:NorthAmericanOTCHealthcareMember2024-04-012025-03-310001295947pbh:OralCareMemberpbh:InternationalOTCHealthcareMember2024-04-012025-03-310001295947pbh:OralCareMember2024-04-012025-03-310001295947pbh:OtherOtcMemberpbh:NorthAmericanOTCHealthcareMember2024-04-012025-03-310001295947pbh:OtherOtcMemberpbh:InternationalOTCHealthcareMember2024-04-012025-03-310001295947pbh:OtherOtcMember2024-04-012025-03-310001295947pbh:AnalgesicsMemberpbh:NorthAmericanOTCHealthcareMember2023-04-012024-03-310001295947pbh:AnalgesicsMemberpbh:InternationalOTCHealthcareMember2023-04-012024-03-310001295947pbh:AnalgesicsMember2023-04-012024-03-310001295947pbh:CoughAndColdMemberpbh:NorthAmericanOTCHealthcareMember2023-04-012024-03-310001295947pbh:CoughAndColdMemberpbh:InternationalOTCHealthcareMember2023-04-012024-03-310001295947pbh:CoughAndColdMember2023-04-012024-03-310001295947pbh:WomensHealthMemberpbh:NorthAmericanOTCHealthcareMember2023-04-012024-03-310001295947pbh:WomensHealthMemberpbh:InternationalOTCHealthcareMember2023-04-012024-03-310001295947pbh:WomensHealthMember2023-04-012024-03-310001295947pbh:GastrointestinalMemberpbh:NorthAmericanOTCHealthcareMember2023-04-012024-03-310001295947pbh:GastrointestinalMemberpbh:InternationalOTCHealthcareMember2023-04-012024-03-310001295947pbh:GastrointestinalMember2023-04-012024-03-310001295947pbh:EyeAndEarCareMemberpbh:NorthAmericanOTCHealthcareMember2023-04-012024-03-310001295947pbh:EyeAndEarCareMemberpbh:InternationalOTCHealthcareMember2023-04-012024-03-310001295947pbh:EyeAndEarCareMember2023-04-012024-03-310001295947pbh:DermatologicalsMemberpbh:NorthAmericanOTCHealthcareMember2023-04-012024-03-310001295947pbh:DermatologicalsMemberpbh:InternationalOTCHealthcareMember2023-04-012024-03-310001295947pbh:DermatologicalsMember2023-04-012024-03-310001295947pbh:OralCareMemberpbh:NorthAmericanOTCHealthcareMember2023-04-012024-03-310001295947pbh:OralCareMemberpbh:InternationalOTCHealthcareMember2023-04-012024-03-310001295947pbh:OralCareMember2023-04-012024-03-310001295947pbh:OtherOtcMemberpbh:NorthAmericanOTCHealthcareMember2023-04-012024-03-310001295947pbh:OtherOtcMemberpbh:InternationalOTCHealthcareMember2023-04-012024-03-310001295947pbh:OtherOtcMember2023-04-012024-03-310001295947pbh:NorthAmericanOTCHealthcareMember2023-04-012024-03-310001295947pbh:InternationalOTCHealthcareMember2023-04-012024-03-310001295947country:US2025-04-012026-03-310001295947country:US2024-04-012025-03-310001295947country:US2023-04-012024-03-310001295947us-gaap:NonUsMember2025-04-012026-03-310001295947us-gaap:NonUsMember2024-04-012025-03-310001295947us-gaap:NonUsMember2023-04-012024-03-310001295947country:US2026-03-310001295947country:US2025-03-310001295947us-gaap:NonUsMember2026-03-310001295947us-gaap:NonUsMember2025-03-310001295947us-gaap:PerformanceSharesMemberus-gaap:SubsequentEventMember2026-05-042026-05-040001295947us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMember2026-05-042026-05-040001295947us-gaap:SubsequentEventMember2026-05-042026-05-040001295947us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMemberus-gaap:SubsequentEventMember2026-05-042026-05-040001295947us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMemberus-gaap:SubsequentEventMember2026-05-042026-05-040001295947us-gaap:EmployeeStockOptionMemberus-gaap:SubsequentEventMember2026-05-042026-05-040001295947pbh:LaCouriumHealthMemberus-gaap:SubsequentEventMember2026-04-012026-05-140001295947us-gaap:SalesReturnsAndAllowancesMember2025-03-310001295947us-gaap:SalesReturnsAndAllowancesMember2025-04-012026-03-310001295947us-gaap:SalesReturnsAndAllowancesMember2026-03-310001295947pbh:CashDiscountsMember2025-03-310001295947pbh:CashDiscountsMember2025-04-012026-03-310001295947pbh:CashDiscountsMember2026-03-310001295947us-gaap:AllowanceForCreditLossMember2025-03-310001295947us-gaap:AllowanceForCreditLossMember2025-04-012026-03-310001295947us-gaap:AllowanceForCreditLossMember2026-03-310001295947us-gaap:SalesReturnsAndAllowancesMember2024-03-310001295947us-gaap:SalesReturnsAndAllowancesMember2024-04-012025-03-310001295947pbh:CashDiscountsMember2024-03-310001295947pbh:CashDiscountsMember2024-04-012025-03-310001295947us-gaap:AllowanceForCreditLossMember2024-03-310001295947us-gaap:AllowanceForCreditLossMember2024-04-012025-03-310001295947us-gaap:SalesReturnsAndAllowancesMember2023-03-310001295947us-gaap:SalesReturnsAndAllowancesMember2023-04-012024-03-310001295947pbh:CashDiscountsMember2023-03-310001295947pbh:CashDiscountsMember2023-04-012024-03-310001295947us-gaap:AllowanceForCreditLossMember2023-03-310001295947us-gaap:AllowanceForCreditLossMember2023-04-012024-03-3100012959472026-01-012026-03-31\n\n                        \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nFORM 10-K\n\n(Mark One)\n\n ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the fiscal year ended March 31, 2026\n\nor\n\n ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from _________ to ____________\n\nCommission file number: 001-32433\n\nPRESTIGE CONSUMER HEALTHCARE INC.\n\n(Exact name of registrant as specified in its charter)\n\nDelaware20-1297589\n\n(State or other jurisdiction of\nincorporation or organization)(I.R.S. Employer Identification No.)\n\n660 White Plains Road\n\nTarrytown, New York 10591\n\n(Address of principal executive offices) (Zip Code)\n\n(914) 524-6800\n\n(Registrant's telephone number, including area code)\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading Symbol(s)Name of each exchange on which registered\n\nCommon stock, par value $0.01 per sharePBHNew York Stock Exchange\n\nSecurities registered pursuant to Section 12(g) of the Act:  None\n\nIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes ☒ No ☐\n\nIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.      Yes ☐ No ☒\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\nLarge accelerated filer☒Accelerated filer☐\n\nNon-accelerated filer☐Smaller reporting company☐\n\nEmerging growth company☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.\n\n☒\n\nIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐\n\nIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes ☐ No ☒\n\nThe aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter ended September 30, 2025 was $2,970.2 million.\n\nAs of May 12, 2026, the registrant had 47,372,166 shares of common stock outstanding.\n\nDOCUMENTS INCORPORATED BY REFERENCE\n\nPortions of the registrant’s Definitive Proxy Statement for the 2026 Annual Meeting of Stockholders (the “2026 Proxy Statement”) are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent described herein.\n\nTABLE OF CONTENTS\n\n   \n\n  Page\n\nPart I"}